Related Experiment Video
Updated: Jul 1, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary
Kornel Fulop Lakatos1, László Kalmár2, Erika Lahm3
1Faculty of Health and Sport Sciences, Széchenyi István University, 1 Egyetem ter, 9026 Győr, Hungary.
Abstract:
Pembrolizumab is a programmed cell death protein (PD-1) inhibitor, humanized antibody widely used in cancer immunotherapy. Choriocarcinoma is an aggressive type of gestational trophoblastic neoplasia. Its treatment is based on surgical removal of the tumorous tissue and systemic chemotherapy; however, in some chemoresistant cases, immunotherapy can also be a valid option. Here, we report the first successful programmed death inhibitor-based treatment of a patient diagnosed with stage IV, ultra-high-risk choriocarcinoma in Hungary.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers